These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 32086342)

  • 1. RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.
    Kohlmeyer JL; Kaemmer CA; Pulliam C; Maharjan CK; Samayoa AM; Major HJ; Cornick KE; Knepper-Adrian V; Khanna R; Sieren JC; Leidinger MR; Meyerholz DK; Zamba KD; Weimer JM; Dodd RD; Darbro BW; Tanas MR; Quelle DE
    Clin Cancer Res; 2020 Jun; 26(12):2997-3011. PubMed ID: 32086342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
    Kohlmeyer JL; Kaemmer CA; Umesalma S; Gourronc FA; Klingelhutz AJ; Quelle DE
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.
    Kohlmeyer JL; Lingo JJ; Kaemmer CA; Scherer A; Warrier A; Voigt E; Raygoza Garay JA; McGivney GR; Brockman QR; Tang A; Calizo A; Pollard K; Zhang X; Hirbe AC; Pratilas CA; Leidinger M; Breheny P; Chimenti MS; Sieren JC; Monga V; Tanas MR; Meyerholz DK; Darbro BW; Dodd RD; Quelle DE
    Clin Cancer Res; 2023 Sep; 29(17):3484-3497. PubMed ID: 37410426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapies for MPNSTs targeting RABL6A-RB1 signaling.
    Kohlmeyer JL; Gordon DJ; Tanas MR; Dodd RD; Monga V; Darbro BW; Quelle DE
    Oncotarget; 2021 Jan; 12(1):10-14. PubMed ID: 33456709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linking FOXM1 and PD-L1 to CDK4/6-MEK targeted therapy resistance in malignant peripheral nerve sheath tumors.
    Lingo JJ; Voigt E; Quelle DE
    Oncotarget; 2024 Sep; 15():638-643. PubMed ID: 39347707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth.
    Umesalma S; Kaemmer CA; Kohlmeyer JL; Letney B; Schab AM; Reilly JA; Sheehy RM; Hagen J; Tiwari N; Zhan F; Leidinger MR; O'Dorisio TM; Dillon J; Merrill RA; Meyerholz DK; Perl AL; Brown BJ; Braun TA; Scott AT; Ginader T; Taghiyev AF; Zamba GK; Howe JR; Strack S; Bellizzi AM; Narla G; Darbro BW; Quelle FW; Quelle DE
    J Clin Invest; 2019 Mar; 129(4):1641-1653. PubMed ID: 30721156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo.
    Kohlmeyer JL; Kaemmer CA; Lingo JJ; Voigt E; Leidinger MR; McGivney GR; Scherer A; Koppenhafer SL; Gordon DJ; Breheny P; Meyerholz DK; Tanas MR; Dodd RD; Quelle DE
    Neurooncol Adv; 2022; 4(1):vdac047. PubMed ID: 35571990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galectin-1 inhibition induces cell apoptosis through dual suppression of CXCR4 and Ras pathways in human malignant peripheral nerve sheath tumors.
    Shih TC; Fan Y; Kiss S; Li X; Deng XN; Liu R; Chen XJ; Carney R; Chen A; Ghosh PM; Lam KS
    Neuro Oncol; 2019 Nov; 21(11):1389-1400. PubMed ID: 31127849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer.
    Beck TN; Georgopoulos R; Shagisultanova EI; Sarcu D; Handorf EA; Dubyk C; Lango MN; Ridge JA; Astsaturov I; Serebriiskii IG; Burtness BA; Mehra R; Golemis EA
    Mol Cancer Ther; 2016 Oct; 15(10):2486-2497. PubMed ID: 27507850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.
    Gampala S; Shah F; Zhang C; Rhodes SD; Babb O; Grimard M; Wireman RS; Rad E; Calver B; Bai RY; Staedtke V; Hulsey EL; Saadatzadeh MR; Pollok KE; Tong Y; Smith AE; Clapp DW; Tee AR; Kelley MR; Fishel ML
    Br J Cancer; 2021 Apr; 124(9):1566-1580. PubMed ID: 33658640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Inhibition of CDK4/6 and XPO1 Induces Senescence With Acquired Vulnerability to CRBN-Based PROTAC Drugs.
    Wang H; Yuan S; Zheng Q; Zhang S; Zhang Q; Ji S; Wang W; Cao Y; Guo Y; Yang X; Geng H; Yang F; Xi S; Jin G; Zhang J; Gao Q; Bernards R; Qin W; Wang C
    Gastroenterology; 2024 Jun; 166(6):1130-1144.e8. PubMed ID: 38262581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.
    Hsieh FF; Barnett LA; Green WF; Freedman K; Matushansky I; Skoultchi AI; Kelley LL
    Blood; 2000 Oct; 96(8):2746-54. PubMed ID: 11023508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner.
    Hagen J; Muniz VP; Falls KC; Reed SM; Taghiyev AF; Quelle FW; Gourronc FA; Klingelhutz AJ; Major HJ; Askeland RW; Sherman SK; O'Dorisio TM; Bellizzi AM; Howe JR; Darbro BW; Quelle DE
    Cancer Res; 2014 Nov; 74(22):6661-70. PubMed ID: 25273089
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Oppel F; Ki DH; Zimmerman MW; Ross KN; Tao T; Shi H; He S; Aster JC; Look AT
    Dis Model Mech; 2020 Aug; 13(8):. PubMed ID: 32651197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.
    Teh JLF; Purwin TJ; Han A; Chua V; Patel P; Baqai U; Liao C; Bechtel N; Sato T; Davies MA; Aguirre-Ghiso J; Aplin AE
    Mol Cancer Ther; 2020 Aug; 19(8):1719-1726. PubMed ID: 32430489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
    Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
    J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribociclib mitigates cisplatin-associated kidney injury through retinoblastoma-1 dependent mechanisms.
    Kim JY; Jayne LA; Bai Y; Feng MJHH; Clark MA; Chung S; W Christman J; Cianciolo RE; Pabla NS
    Biochem Pharmacol; 2020 Jul; 177():113939. PubMed ID: 32229099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer.
    Dang F; Nie L; Zhou J; Shimizu K; Chu C; Wu Z; Fassl A; Ke S; Wang Y; Zhang J; Zhang T; Tu Z; Inuzuka H; Sicinski P; Bass AJ; Wei W
    Nat Commun; 2021 Sep; 12(1):5386. PubMed ID: 34508104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional imaging of RAS pathway targeting in malignant peripheral nerve sheath tumor cells and xenografts.
    Butler E; Schwettmann B; Geboers S; Hao G; Kim J; Nham K; Sun X; Laetsch TW; Xu L; Williams NS; Skapek SX
    Pediatr Blood Cancer; 2020 Dec; 67(12):e28639. PubMed ID: 32975370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.